Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2017-02-22 Call Transcript
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 8-K
Call Transcript Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 21, 2017, by Cidara Therapeutics, Inc. It announces a conference call to discuss the results of a Phase 2 clinical trial. The key detail is that the document includes a conference call transcript as Exhibit 99.1. The text explicitly states that the transcript is attached and incorporated by reference. The content is primarily about the conference call and its transcript, not a full financial report or other filing type. Therefore, the document fits the category of a Call Transcript (CT). The length of the document (4647 characters) supports that it is not a brief announcement but includes substantive transcript content.
2017-02-22 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release about clinical trial results and the discontinuation of a development program. It does not contain detailed financial statements or comprehensive financial analysis. The document length is 3660 characters, which is relatively short and includes a press release as an exhibit. The content is an announcement of a significant event rather than a full financial report or earnings release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2017-02-21 English
SC 13G/A
Major Shareholding Notification
2017-02-15 English
SC 13G/A
Major Shareholding Notification
2017-02-14 English
SC 13G/A
Major Shareholding Notification
2017-02-14 English
Major Shareholding Notification 2017
Major Shareholding Notification
2017-02-14 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.